Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F18%3AE0107180" target="_blank" >RIV/00843989:_____/18:E0107180 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/18:A1901YVH

Výsledek na webu

<a href="http://dx.doi.org/10.1038/s41375-018-0040-1" target="_blank" >http://dx.doi.org/10.1038/s41375-018-0040-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-018-0040-1" target="_blank" >10.1038/s41375-018-0040-1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Popis výsledku v původním jazyce

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

Název v anglickém jazyce

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Popis výsledku anglicky

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

1476-5551

Svazek periodika

32

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

19

Strana od-do

1542-1560

Kód UT WoS článku

000438062500007

EID výsledku v databázi Scopus

2-s2.0-85046372246